About the Company
Gritstone bio is a clinical-stage American biotechnology company which develops cancer and infectious disease immunotherapies and vaccines. It was founded in August 2015 as Gritstone Oncology, Inc., and is based in Emeryville, California. In September 2021 it raised $55.0 million from the sale of 5,000,000 shares.It started a Phase 1 trial of its self-amplifying mRNA second generation SARS-CoV-2 vaccine, GRT-R910, in the NIHCR Manchester Clinical Research Facility at Manchester Royal Infirmary, in September 2021. This is to explore the ability of GRT-R910 to boost and expand the immunogenicity of AstraZeneca's first-generation COVID-19 vaccine AZD1222 (Vaxzevria) in healthy adults of more than 60 years. It uses lipid nanoparticles to deliver a broad set of antigens against SARS-CoV-2 that includes both stabilized spike protein and highly conserved viral protein regions containing T cell epitopes. Prof. Andrew Ustianowski is the study’s chief investigator.On 10 November 2021, Gritstone announced positive preclinical data of its second-generation self-amplifying mRNA (SAM) vaccine against SARS-CoV-2 in non-human primate models.It is involved in a Phase 1/2 study, in collaboration with Bristol Myers Squibb, in 26 patients with metastatic solid tumors.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GRTS News
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering
Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE ---- Discovery ...
What's Going On With Small Cap Cancer Vaccine Focused Gritstone Bio Stock On Tuesday?
Gritstone Bio Inc (NASDAQ:GRTS) released preliminary data from the ongoing, signal-seeking Phase 2 portion of the Phase 2/3 ...
Gritstone bio Announces Proposed Public Offering
Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024
About Gritstone bioGritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and ...
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering
EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...
Gritstone Bio Inc GRTS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Gritstone bio Presents Improvements to EDGE(TM) Platform at AACR 2024
April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today presented an ...
Gritstone bio Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...